Use of MVA to treat prostate cancer
First Claim
Patent Images
1. A recombinant modified vaccinia virus Ankara (MVA) expressing a polypeptide comprising a human prostatic acid phosphatase (PAP) antigen, wherein the recombinant MVA virus induces B-cell and T-cell immune responses against the human PAP antigen when administered to a human host.
2 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B-and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or after a taxane.
-
Citations
23 Claims
- 1. A recombinant modified vaccinia virus Ankara (MVA) expressing a polypeptide comprising a human prostatic acid phosphatase (PAP) antigen, wherein the recombinant MVA virus induces B-cell and T-cell immune responses against the human PAP antigen when administered to a human host.
Specification